[{"id":"2ea10697-59e6-44be-8de4-6d4375c12a63","acronym":"COMPANION-003","url":"https://clinicaltrials.gov/study/NCT05513742","created_at":"2023-07-24T16:08:41.037Z","updated_at":"2024-07-02T16:35:11.967Z","phase":"Phase 2","brief_title":"A Study of CTX-009 in Adult Patients With Metastatic Colorectal Cancer","source_id_and_acronym":"NCT05513742 - COMPANION-003","lead_sponsor":"Compass Therapeutics","biomarkers":" HER-2 • BRAF • MSI","pipe":" | ","alterations":" HER-2 positive • BRAF V600E • MSI-H/dMMR • BRAF V600","tags":["HER-2 • BRAF • MSI"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • BRAF V600E • MSI-H/dMMR • BRAF V600"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e tovecimig (CTX-009)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 84","initiation":"Initiation: 12/08/2022","start_date":" 12/08/2022","primary_txt":" Primary completion: 06/01/2024","primary_completion_date":" 06/01/2024","study_txt":" Completion: 12/01/2024","study_completion_date":" 12/01/2024","last_update_posted":"2024-04-02"}]